PRMT2 CRISPR/Cas9 KO Plasmid (m): sc-420951
- Target species: mouse
- 20 µg of transfection-ready, purified plasmid DNA; Suitable for up to 20 transfections
- PRMT2 CRISPR/Cas9 Knockout (KO) Plasmid (m) is a pool of plasmids, each encoding Cas9 nuclease and a target-specific 20 nt guide RNA (gRNA) designed for maximum knockout efficiency using sequences derived from the GeCKO v2 library
- gRNA sequences direct Cas9 to induce site-specific double-strand breaks (DSBs) in the PRMT2 genomic locus, resulting in gene knockout through non-homologous end joining (NHEJ)
- The puromycin resistance and RFP genes are flanked by LoxP sites, enabling removal of selection markers via Cre recombinase (Cre Vector: sc-418923) after establishing stable knockout cell lines
- Following transfection, gene knockout efficiency can be assayed by WB, IF or IHC using antibody: PRMT2 Antibody (B-11): sc-393254
Ordering Information
| Product Name | Catalog # | UNIT | Price | Qty | FAVORITES | |
PRMT2 CRISPR/Cas9 KO Plasmid (m) | sc-420951 | 20 µg | $397.00 |
Overview
Prmt2 encodes protein arginine methyltransferase 2 (PRMT2), a type I PRMT that catalyzes asymmetric dimethylation of arginine residues on histones and non-histone substrates to modulate chromatin structure and protein function. PRMT2 activity influences transcriptional regulation and co-regulator dynamics in nuclear receptor and other signaling pathways, linking arginine methylation to context-dependent gene expression programs. In mouse systems, PRMT2 has been associated with control of cell proliferation, differentiation, and inflammatory gene regulation through epigenetic and post-translational mechanisms. Dysregulated PRMT2-dependent methylation and transcriptional networks have been implicated in disease-relevant processes such as tumor-associated signaling, metabolic stress responses, and immune dysregulation, supporting its use as a mechanistic node in pathway studies.
PRMT2 CRISPR/Cas9 KO Plasmid (m) is a pool of plasmids designed for targeted disruption of the Prmt2 gene in mouse cell lines. Each plasmid co-expresses a unique single guide RNA (sgRNA) targeting a distinct site within the Prmt2 together with the Streptococcus pyogenes Cas9 nuclease. The plasmids also encode GFP, allowing fluorescent identification and enrichment of successfully transfected cells by fluorescence microscopy or flow cytometry.
The multi-guide design increases the likelihood of generating insertions or deletions (indels) that disrupt the Prmt2 open reading frame following Cas9-mediated double-strand break formation. DNA breaks introduced by the CRISPR/Cas9 system are repaired through endogenous non-homologous end joining (NHEJ) pathways, frequently resulting in frameshift mutations that abolish PRMT2 protein expression.
This CRISPR knockout system enables efficient generation of Prmt2-deficient cell models for investigation of PRMT2 signaling, functional genomics studies, cancer biology research, and evaluation of therapeutic responses in human cell lines.
Key Features
- sgRNAs targeting Prmt2 exon(s) critical for PRMT2 function
- Co-expression of SpCas9 and sgRNA from a single plasmid for simplified delivery
- GFP reporter for identification of transfected cells
- Pool of plasmids targeting multiple Prmt2 genomic sites to improve knockout efficiency
- Compatible with delivery by transfection
Design Variants
CRISPRs +/- HDRs
- gRNAs encoded by PRMT2 CRISPR/Cas9 KO Plasmid (m) and PRMT2 CRISPR/Cas9 KO Plasmid (m2) target distinct sites within the Prmt2 locus. One or both targeting designs may be available. See Related Products for availability.
- HDR donor constructs encoded by PRMT2 HDR Plasmid (m) and PRMT2 HDR Plasmid (m2) contain a puromycin resistance cassette and an RFP reporter flanked by Prmt2 homology arms to support homology-directed repair at defined Prmt2 target sites corresponding to the CRISPR/Cas9 KO designs. HDR donor availability may vary. See Related Products for availability.
For Research Use Only. Not Intended for Diagnostic or Therapeutic Use.